Celldex Therapeutics halted development of its experimental eczema treatment on Thursday after the drug missed primary and secondary goals in a mid-stage trial. Shares fell 3.2% in extended trading following the announcement. The trial failure forces the drug developer to abandon its atopic dermatitis program entirely.

Trial Results and Drug Performance